{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:47:23Z","timestamp":1761742043708},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1273,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,7]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Proton pump inhibitors such as omeprazole produce a long\u2010lasting inhibition of gastric acid secretion associated with significant increases in plasma gastrin. Rabeprazole (E3810) is a new substituted benzimidazole H<jats:sup>+<\/jats:sup>,K<jats:sup>+<\/jats:sup> ATPase inhibitor. It acts as an irreversible, non\u2010competitive inhibitor of the H<jats:sup>+<\/jats:sup>,K<jats:sup>+<\/jats:sup> ATPase and preliminary studies demonstrate that rabeprazole produces a potent and long\u2010lasting inhibition of gastric acid secretion and a low level of hypergastrinaemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>This randomized, double\u2010blind, placebo\u2010controlled study was performed to further examine the effects of different single doses of rabeprazole on gastric acid secretion and serum gastrin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In this study, four groups of 10 healthy, non\u2010smoking <jats:italic>Helicobacter pylori<\/jats:italic>\u2010negative men (mean age 22.5\u2003\u00b1\u20033.9\u2003years) received single oral doses of 10, 20, 30 and 40\u2003mg of rabeprazole. Two of the 10 volunteers in each group received placebo as part of the double\u2010blind study design. All volunteers who entered into the study had a normal gastric acid secretory capacity as evaluated by pentagastrin challenge. Prior to administration of the first dose of test drug, volunteers underwent an inpatient 24\u2010h measurement of baseline intragastric pH. One week later, volunteers received the test drug and again underwent an inpatient 24\u2010h measurement of intragastric pH. During both periods, plasma samples were collected at specified intervals over 48\u2003h and were sent for analysis of rabeprazole and gastrin levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Administration of rabeprazole resulted in a dose\u2010dependent increase in the duration and extent of intragastric pH elevation. The response among all volunteers receiving drug was significantly different from placebo, with greater acid inhibition occurring in the 30 and 40\u2003mg groups. In addition, there was also a dose\u2010related increase in plasma gastrin. The pharmacokinetics of rabeprazole were similar to those of other proton pump inhibitors with a <jats:italic>t<jats:sub>1\/2<\/jats:sub><\/jats:italic> of between 0.7 and 1.0\u2003h. There were no clinically significant effects on patient laboratory tests or serious adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The results of this study suggest that rabeprazole is as potent as omeprazole and lansoprazole in inhibiting gastric acid secretion.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00356.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:36:46Z","timestamp":1047353806000},"page":"667-672","source":"Crossref","is-referenced-by-count":14,"title":["An ascending single\u2010dose safety and tolerance study of an oral formulation of rabeprazole (E3810)"],"prefix":"10.1111","volume":"12","author":[{"family":"Lew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Barbuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Sytnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Humphries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.19.182"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90719-L"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.44.552"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259747"},{"key":"e_1_2_6_6_2","first-page":"99","article-title":"A study of the effects of the proton pump inhibitor E3810 (rabeprazole sodium) on gastric pH","volume":"41","author":"Inoue M","year":"1994","journal-title":"Jpn Arch Int Med"},{"key":"e_1_2_6_7_2","first-page":"23","article-title":"An open randomized dose\u2013response trial of two doses of E3810 (rabeprazole sodium) in patients with duodenal or gastric ulcers, with 24 hour pH monitoring in gastric ulcer patients","volume":"14","author":"Motomura A","year":"1994","journal-title":"Modern Physician"},{"key":"e_1_2_6_8_2","first-page":"143","article-title":"A study of the effects of the proton pump inhibitor E3810 (rabeprazole sodium) on gastric juice secretion","volume":"41","author":"Inoue M","year":"1994","journal-title":"Jpn Arch Int Med"},{"key":"e_1_2_6_9_2","unstructured":"SakegushiM AshidaK OhsibaS.A Comparison of the Effects of 7 Days Dosing of the Proton Pump Inhibitor E3810 or Omeprazole on Intragastric pH Serum and Urinary Levels in Healthy Volunteer. Tokyo Japan: Eisai Co. Ltd 1996."},{"key":"e_1_2_6_10_2","unstructured":"HongoM OharaS AsakiS et al.A comparison of Two Doses of the Proton Pump Inhibitor E3810 (Rabeprazole Sodium) Versus Famotidine and Pirenzepine Using a 24 Hour Monitoring of Gastric pH in Healthy Volunteers. Tokyo Japan: Eisai Co. Ltd 1996."},{"key":"e_1_2_6_11_2","first-page":"51","article-title":"Long term acid control and proton pump inhibitors: interactions and safety issues in perspective","volume":"92","author":"Freston JW","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00583.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00394.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.24.4.270"},{"key":"e_1_2_6_15_2","unstructured":"SakagushiK AshidaS OhshibaS FukaiM.Inhibitory effect of the novel proton pump inhibitor E3810 on gastric acid secretion as clinically determined by intragastric pH monitoring. Abstract at 10th world congress of Gastroenterology Los Angeles CA. Am J Gastroenterol 1994; 89 (Suppl. 8): 684."},{"key":"e_1_2_6_16_2","first-page":"527","article-title":"Control of acid secretion","volume":"21","author":"Shamburek RD","year":"1993","journal-title":"Gastroenterol Pharm"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091241"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259540"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199142010-00008"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199244020-00007"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000201275"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280061"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02440862"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00356.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00356.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00356.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T12:06:29Z","timestamp":1694433989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00356.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1998,7]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00356.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00356.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,7]]}}}